Comparative Pharmacology
Head-to-head clinical analysis: PROAIR DIGIHALER versus PROAIR HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROAIR DIGIHALER versus PROAIR HFA.
PROAIR DIGIHALER vs PROAIR HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, resulting in bronchodilation.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.
None Documented
None Documented
Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation
Terminal elimination half-life: 3.8 to 5 hours; clinically, this supports a dosing interval of every 4-6 hours as needed for symptom relief.
Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2%
Renal: approximately 72% as unchanged drug and metabolites; fecal: approximately 10%; biliary: minimal.
Category C
Category C
Beta-2 Agonist Bronchodilator
Beta-2 Agonist Bronchodilator